These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24674814)

  • 1. Pharmacology should be at the centre of all preclinical and clinical studies on new psychoactive substances (recreational drugs).
    Green AR; Nutt DJ
    J Psychopharmacol; 2014 Aug; 28(8):711-8. PubMed ID: 24674814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase/1st communication: The contribution of clinical pharmacology].
    Kuhlmann J
    Arzneimittelforschung; 2004; 54(5):251-8. PubMed ID: 15212186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increasing use of 'party drugs' in people living with HIV on antiretrovirals: a concern for patient safety.
    Bracchi M; Stuart D; Castles R; Khoo S; Back D; Boffito M
    AIDS; 2015 Aug; 29(13):1585-92. PubMed ID: 26372268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug interactions between common illicit drugs and prescription therapies.
    Lindsey WT; Stewart D; Childress D
    Am J Drug Alcohol Abuse; 2012 Jul; 38(4):334-43. PubMed ID: 22221229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models.
    Lowe PJ; Tannenbaum S; Wu K; Lloyd P; Sims J
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):195-209. PubMed ID: 20050847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limited use of novel psychoactive substances in South London nightclubs.
    Wood DM; Hunter L; Measham F; Dargan PI
    QJM; 2012 Oct; 105(10):959-64. PubMed ID: 22718853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Historical View and Vision into the Future of the Field of Safety Pharmacology.
    Bass AS; Hombo T; Kasai C; Kinter LB; Valentin JP
    Handb Exp Pharmacol; 2015; 229():3-45. PubMed ID: 26091634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase/2nd communication: promising strategies].
    Kuhlmann J
    Arzneimittelforschung; 2004; 54(6):307-13. PubMed ID: 15282874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current approaches and issues in non-clinical evaluation of abuse and dependence.
    Moser P; Wolinsky T; Castagné V; Duxon M
    J Pharmacol Toxicol Methods; 2011; 63(2):160-7. PubMed ID: 20868759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of an NIH consortium for preclinicAl AssESsment of CARdioprotective therapies (CAESAR): a paradigm shift in studies of infarct size limitation.
    Lefer DJ; Bolli R
    J Cardiovasc Pharmacol Ther; 2011; 16(3-4):332-9. PubMed ID: 21821536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of study characteristics with estimates of effect size in studies of ecstasy use.
    Taylor EM; Greene NM; Morgan CJ; Munafò MR
    J Psychopharmacol; 2011 Nov; 25(11):1573-7. PubMed ID: 21937685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The risky cocktail: what combination effects can we expect between ecstasy and other amphetamines?
    Dias da Silva D; Carmo H; Silva E
    Arch Toxicol; 2013 Jan; 87(1):111-22. PubMed ID: 23001138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raising awareness of new psychoactive substances: chemical analysis and in vitro toxicity screening of 'legal high' packages containing synthetic cathinones.
    Araújo AM; Valente MJ; Carvalho M; Dias da Silva D; Gaspar H; Carvalho F; de Lourdes Bastos M; Guedes de Pinho P
    Arch Toxicol; 2015 May; 89(5):757-71. PubMed ID: 24903018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Research in the field of clinical pharmacology in the USSR].
    Lakin KM; Makarov VA; Novikova NV
    Farmakol Toksikol; 1982; 45(3):5-12. PubMed ID: 7047211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").
    Green AR; Mechan AO; Elliott JM; O'Shea E; Colado MI
    Pharmacol Rev; 2003 Sep; 55(3):463-508. PubMed ID: 12869661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical toxicology of newer recreational drugs.
    Hill SL; Thomas SH
    Clin Toxicol (Phila); 2011 Oct; 49(8):705-19. PubMed ID: 21970769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology.
    Gabrielsson J; Green AR
    J Pharmacol Exp Ther; 2009 Dec; 331(3):767-74. PubMed ID: 19779129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug research: from the idea to the product.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Dec; 35(12):541-52. PubMed ID: 9455711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benzylpiperazine: a drug of abuse?
    Johnstone AC; Lea RA; Brennan KA; Schenk S; Kennedy MA; Fitzmaurice PS
    J Psychopharmacol; 2007 Nov; 21(8):888-94. PubMed ID: 17606471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.